There’s an assumption that still shows up in how scale is discussed across advanced therapies, even if it’s rarely stated outright. Once a program proves itself clinically, scale is expected to follow a recognizable path, one that mirrors traditional biopharmaceutical development. Capacity expands proportionally, throughput increases, and what was once constrained (geographies, patient populations, clinical sites) begins to open. It’s a familiar growth path, and in most areas of biopharma, it holds true.
But for cell and gene therapies (CGTs), it just doesn’t translate cleanly.
In CGT, nothing about the process becomes more compressible as demand grows. A patient-specific, individualized therapy doesn’t lend itself to aggregation, and it doesn’t benefit from the same efficiencies that come with larger batch production. Each dose of personalized medicine carries its own timeline and constraints, its own chain of identity and custody that has to remain documented and intact from collection through administration. The process doesn’t stretch to accommodate scale. It repeats.
That repeatability is easy to work with early on, at small patient populations and limited volumes, when everything can be closely managed. It becomes something else entirely as programs move forward into later-stage clinical trials and toward commercialization. What was a coordinated pathway once upon a time now starts to branch. First into a handful of process flows, then into dozens, and eventually into hundreds (or more), all moving in parallel. The work doesn’t simplify as it grows, it just becomes harder to keep aligned.
For advanced therapies, they don’t scale up. They scale out. Instead of the traditional scale-up seen in something like biologics, where you can work with a bigger bioreactor and make a 10,000-dose batch of product, you have to scale out. You end up performing the same N of 1 process 10,000 unique times in parallel. And when personalized medicines scale, consistency doesn’t (and can’t) come from batch processing. It has to be intentionally maintained across an increasing number of independent, high-stakes movements.
As a high-level concept, the shift to wider patient populations and higher volumes sounds like it should be straightforward. But in real life? It starts to change the shape of the entire operating model.
Scaling out means the program isn’t being asked to produce more in aggregate so much as it's being asked to hold together (with consistency) as the number of individual processes grows. Each new clinical site and patient that comes through the doors introduces another sequence of events that has to be coordinated, documented, and implemented within its own window while still adhering to the same underlying standards as every other patient moving through the program at that time.
At a certain point, volume stops being the right lens through which to measure. What begins to matter more is how many parallel paths existing workflows can sustain without losing alignment.
You start to see the strain in places that aren’t always obvious at first. For example, when a small number of collection sites expand into a wider network that spans regions, they begin to compete with one another as more patient material enters the queue. Or shipping lanes that performed predictably at a limited scale now have to perform consistently across a much wider range of routes, conditions, and timelines without introducing variability into material handling or delivery windows.
Nothing about any one task is new, what’s changing is the degree to which they’re all in motion concurrently.
And as that concurrency increases, it’s no longer enough for each step to work independently. The greater end-to-end supply chain needs to operate with continuity across steps that are happening in parallel, and often doing so across multiple locations and teams that were never designed to operate as a single, unified flow.
This is where the strain really begins to surface. In the subtle misalignments. Small differences in how collections are managed between sites or variations in how long fresh leukapheresis-derived material takes to arrive at manufacturing. The additional coordination required to reconcile collections and manufacturing timelines that no longer line up as cleanly as they once did. And before you know it, new instances of friction have been introduced into a system that relies on precision.
And because with advanced therapies, each patient’s therapy is individualized, there’s no batch-level redundancy to smooth over that friction. Every movement, every handoff, carries with it the weight of a patient’s hope for what is likely their only chance at lifesaving treatment.
Scale-out doesn’t break the supply chain in obvious ways. It pressure-tests whether the supply chain was ever truly operating as a continuous, integrated chain to begin with.
Why Scale-Out is a Synchronization Problem Disguised as a Scale Problem
What starts to become clear at this stage of expansion is that the limitation isn’t volume, at least not in the traditional sense.
Programs aren’t struggling because they can’t move more material or support more patients. They’re struggling because the effort required to keep everything aligned increases faster than the supply chain was designed to support. The challenge shifts from throughput to coordination, and more specifically, to synchronization.
Under scale-out conditions, every patient-specific pathway has to remain consistent. Not just on a case-by-case basis per patient, but in relation to the broader infrastructure moving alongside it. Timelines have to hold across collections, manufacturing, and administration, even as variability is introduced as programs grow. Material has to move through expanded regions and environments without introducing differences in how it's handled or in the timelines it follows. Decisions made upstream can’t carry unpredictably downstream when dozens or hundreds of parallel workflows are already in motion.
At smaller, early-phase scale, that coordination is largely human and tightly controlled. A clinical team knows exactly where the patient is and when to schedule their collection. They know where materials are as they move through the supply chain to manufacturing and later to patient administration. Every link in the supply chain is visible and directly managed.
But as concurrency increases and the number of sites and patients grows more complex, what was once manageable with direct oversight now starts to feel the strain. And, at a certain point, coordination stops being a viable mechanism for maintaining alignment. The volume of interdependent processes outpaces what can be managed through visibility and intervention, and what was once a tightly coordinated supply chain, out of necessity, needs to become something operating with a greater degree of autonomy, even as the stakes remain the same.
Synchronization in that context isn’t as straightforward as refining coordination. It’s a different model entirely. It requires the supply chain to carry alignment as a built-in property of how it operates rather than something that needs to be actively maintained at every step.
And that’s where the distinction becomes critical. Because synchronization isn’t something that can be layered onto the supply chain after the fact. It has to be embedded into the end-to-end operational workflow from the beginning. All of the choices made along the way about how processes are defined and how handoffs are managed, how data is captured and maintained in an audit-ready state… it all impacts how variability is absorbed without creating divergence.
Without that, scale-out doesn’t necessarily fail outright. But what was once predictable and aligned (thanks to direct oversight and manual efforts, in many cases) begins to drift. And the effort required to bring it back into alignment starts to grow alongside the complexity.
What is Takes to Stay Aligned at Scale
If coordination stops being enough, the question becomes what replaces it. Because at scale-out, alignment can’t depend on visibility alone. It can’t rely on teams constantly stepping in to reconcile timelines or adjust for variability, or to bridge gaps between different parts of the workflow.
That model only works when the number of moving pieces is limited, and it becomes increasingly fragile as those pieces (or in the case of personalized therapies, sites and patient doses) multiply.
What tends to hold under the conditions of scale-out is a supply chain where alignment isn’t something that has to be continuously re-established. It’s something that’s already built into the underlying operational workflows. In practice, that looks less like adding oversight and more like reducing the number of ways the supply chain can diverge in the first place. Reducing handoffs between disconnected vendors, increasing continuity in how materials are handled.
It also changes how consistency is defined. In traditional biomanufacturing, consistency comes from repeating the same process for larger volumes and within a controlled environment. But in scale-out models, consistency has to be maintained across environments (different collection sites, geographies, timelines, etc.), all operating under the same expectations.
That requires a different kind of structure.
Not one built around individual functions, each operating well on its own, but one that connects those functions in a way that allows them to operate as part of a single, end-to-end supply chain platform. Where logistics, material handling, biostorage, and supporting processes don’t sit adjacent to one another, but are designed to work together within the same framework.
Because once the number of parallel workflows reach a certain threshold, the distinction becomes clear. Programs that rely on coordination continue to add complexity as they grow. Supply chains that are designed (from the start) for alignment absorb that complexity without multiplying it.
How to Design for Supply Chain Alignment That Supports Scale-Out
This is where the shape and structure of the supply chain start to matter in a different way. If alignment has to be carried by the supply chain itself, then the structure supporting it becomes a defining factor in how well it holds under scale-out conditions. The more the workflow depends on independent components (separate vendors, disconnected processes, multiple quality frameworks), the more coordination it requires to stay aligned.
What tends to hold up are operational workflows that are intentionally structured to reduce the number of stress points where that alignment can break down.
This can’t be done by simplifying the work itself, as the work is inherently complex, but by organizing it so that complexity is managed within an integrated framework rather than across disconnected ones. Where logistics, cryopreservation, biostorage, kitting, and clinical support functions aren’t treated as separate pieces that need to be continuously coordinated, but as parts of an end-to-end supply chain that evolve together as the program grows.
That shift changes how the supply chain behaves.
In an integrated supply chain, handoffs become extensions of the same process rather than transitions between different vendors and operating models. Instead of reconciling data across systems, it’s generated and maintained (in audit-ready state) within a common structure, and variability becomes more easily absorbed at specific points in the workflow without introducing downstream inconsistency because the parameters for how that variability is handled are aligned from the outset.
It also changes how scale itself is supported.
Instead of building standalone capacity in isolated sections of the supply chain and then working to connect them, scale becomes an expansion of an already integrated network.
New sites, new regions, new patient populations all expand within the same underlying processes and quality framework.
In practice, that often means bringing more of the supply chain into a unified operating model, sometimes physically as well as operationally. Co-locating critical services so that activities that would otherwise require coordination across multiple organizations can occur within the same environment.
When logistics are aligned under the same roof as cryopreservation, the movement of time-critical, leukapheresis-derived starting materials is streamlined. When this is further supported by onsite biostorage and BioServices like secondary packaging and labeling, movement between critical services doesn’t introduce new variables. And when all of this is supported by a global footprint, it allows the same model to extend across regions without having to be rebuilt along the way.
This is the kind of structure that allows scale-out to behave like a cohesive operational system rather than a collection of individual vendors and activities.
It’s also what an integrated, end-to-end supply chain platform is designed to provide. Within Cryoport Systems, capabilities that are often managed separately – logistics, advisory support for shipping risk assessments and lane validations, packaging performance qualification, BioServices like kitting and clinical sample management, biostorage, and cryopreservation through the IntegriCell® automated closed process – are brought together within a single operational framework.
And as programs move from early-stage development into clinical trials and toward commercial scale, that framework grows with them. Global Supply Chain Centers bring these capabilities together under one roof where scale demands this level of coordination, while the broader global network enables the same processes and standards to be applied consistently as geographies expand.
The result isn’t just additional capacity. Or disconnected capacity. Or a patchwork of vendors and suppliers. It’s continuity.
And under scale-out conditions, that continuity is what allows growth to happen without losing control of the operational structure along the way.
Where Scale Has Changed Form, Not Importance
Scale has always been a defining milestone in therapy development. It marks the point where something that works in controlled environments begins to reach the patients it was intended for. That hasn’t changed.
What has changed is how scale behaves.
In CGT, reaching more patients doesn’t come from sustaining performance as complexity expands, as N of 1 processes are replicated numerous times in parallel, across more sites and more geographies and within expanded patient populations (and sometimes, for expanded indications). The challenge isn’t simply to grow. It’s to do so without losing alignment along the way. At a certain point, the pressure test of scale stops being about capacity and reflects the structure supporting it.
Whether the supply chain can extend without fragmenting.
Whether consistency can be achieved without requiring constant intervention.
Whether alignment is something that has to be continuously re-established, or something that’s already built into how the program operates.
The answers to these questions shape how reliably a program can progress to the next milestone. How smoothly it can expand. Even how confident investors and regulators are in the story the program is presenting.
Scale hasn’t become less important for CGT because the therapies are personalized. If anything, it matters more. But it no longer follows a familiar path. It has taken a different form.
Programs that recognize that early, and design for synchronization, continuity, and alignment from the earliest stages, are the ones that will be able to carry that scale-out forward without losing control of it along the way.
#IndustryMemberNews